A Phase I/II Study of the Tolerability, Safety and Pharmacokinetics of Oral Monepantel (MPL) in Individuals with Treatment-Refractory Solid Tumours.
Phase 1
- Conditions
- CancerCancer - Any cancer
- Registration Number
- ACTRN12614000612617
- Lead Sponsor
- PharmAust Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Stopped early
- Sex
- All
- Target Recruitment
- 9
Inclusion Criteria
Male or female patients with progressing and unresectable tumours in whom all standard treatments have been exhausted or have been contraindicated.
Life expectancy of at least 3 months, in the opinion of the Investigator.
Exclusion Criteria
Recent treatment (i.e. within 14 days of screening) with any systemic anticancer therapy.
Participants for whom standard therapy exists, and in the view of the Invesigator, is appropriate.
Unresolved recovery from recent major surgery, or unresolved toxicity from recent radiotherapy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method